Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

MRNABullishAnalyst Target Updateanalyst

Medium materiality6/10

Piper Sandler raises Moderna price target to $230 from $167

Oct 26, 2026, 3:36 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The substantial target increase is bullish, but the target remains an analyst estimate rather than a confirmed catalyst.

AI summary

What happened, with direct paths to the underlying reporting

Piper Sandler raised its Moderna target by $63; the $230 target is about 15% above the posted price of $200.10.

Piper Sandler raised MRNA's target to $230 from $167.
Target implies about 15% upside from $200.10.

Key facts

01
Target: $230
02
Posted price: $200.1
03
Analyst firm: Piper Sandler

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Piper Sandler raises Moderna price target to $230 from $167

Key facts

Moderna melanoma trial shows efficacy; market pricing hinges on Data Maturity

Moderna slides after alleged ESMO abstract leak questions intismeran efficacy

Moderna-Merck melanoma vaccine shows 42% risk reduction; ESMO readout may re-rate stock

Moderna eyes Phase 3 melanoma readout; target raised and Nasdaq-100 flag